M3dicine

What M3dicine does

M3dicine is an Australian medical device company (M3DICINE Pty Ltd, founded 2015, headquartered in Eight Mile Plains, Queensland) that develops an AI-enabled electronic stethoscope platform spanning hardware, mobile applications, and a cloud-based portal. Its core product is Stethee Pro, a wireless electronic stethoscope that pairs via Bluetooth with iOS and Android apps to capture heart and lung sounds and run FDA-cleared machine learning algorithms — branded as AIDA — that derive heart rate, respiratory rate, and systole/diastole durations in approximately 20 seconds. The AIDA visualization suite includes AIDA Cycles (phonocardiogram), AIDA Energy (heart valve S1/S2 relative energy), and AIDA Enviro (geolocation and environmental data), and the platform extends to M3DICINE Central, a HIPAA-compliant web portal for patient data, report generation, and clinician-to-clinician data sharing. The company also offers Stethee Vet, a veterinary version with custom digital filters for animal fur noise, and a Stethee Vet Central analytics dashboard. Commercial revenue streams are structured as hardware sales (Stethee Pro, Stethee Vet), recurring subscription access to the mobile apps and M3DICINE Central, and a Clinical Interpretation Service — though as of the source date, both products are explicitly stated as not yet commercially available in any country.

M3dicine operates a B2B, institutionally focused go-to-market: Class II FDA clearance restricts sale to licensed healthcare practitioners, and the company engages major academic medical centers and health systems (UCSF, Prisma Health, Mayo Clinic, Imperial College London, National University Hospital Singapore) for AI algorithm co-development and clinical validation. A flagship initiative is an NIH-funded global TB screening program with UCSF and partners across 11 countries, alongside an India-focused pneumonia AI partnership with SRS Life Sciences and an Australia Zoo Wildlife Hospital collaboration for the veterinary line. Advisory board leadership includes MIT's Professor Anthony Sinskey, and the company has built its quality system to ISO 13485 and U.S. FDA standards. The company is privately held with no disclosed venture funding rounds, suggesting it has been funded through founder capital, grants, and partnerships rather than external venture capital.

The business is anchored in the digital auscultation market, projected to reach approximately $1.85B by 2030 at a 15.7% CAGR, with M3dicine positioned in the AI-enabled segment. Distribution is direct enterprise sales plus mobile app store distribution (iOS, Android) and a regional channel partnership in India. No pricing is publicly disclosed.

Name

M3dicine

Legal name

M3DICINE Pty Ltd

Website

https://m3dicine.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

M3dicine is an Australian medical device company building the FDA-cleared Stethee Pro AI-enabled wireless stethoscope platform — paired with iOS/Android apps and the M3DICINE Central HIPAA-compliant portal — that derives cardiac and respiratory vital signs in 20 seconds for licensed clinicians, plus Stethee Vet for veterinarians.

Ownership category

akta.pro rank

Product category

Digital Auscultation Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industries

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG)

Keywords

• Digital auscultation devices
• AI-enabled stethoscopes
• Electronic stethoscope hardware
• Cardiac respiratory monitoring
• Veterinary diagnostic stethoscopes

Headquarters

HQ city

Eight Mile Plains

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Stethee Pro Device Sales: M3DICINE sells the Stethee Pro electronic stethoscope hardware device. Federal law restricts sale to or on the order of a licensed healthcare practitioner. The device is a Class II FDA-cleared medical device, and the company also sells the Stethee Vet version for veterinary use.
2. Stethee Pro Mobile Application Access: Access to the Stethee Pro Mobile Application (iOS and Android) which provides real-time analysis, recording, playback, patient management, and data sharing capabilities. The app connects to the M3DICINE Central platform for HIPAA-compliant data management.
3. M3DICINE Central Platform: HIPAA-compliant web-based platform for managing patient data, generating reports, and sharing data with colleagues. Available via subscription for healthcare providers. Secure data hosting with third-party cloud providers.
4. Clinical Interpretation Services: The company mentions a 'Clinical Interpretation Service' subject to regional telemedicine restrictions, indicating potential revenue from AI-assisted or physician-mediated clinical interpretation of auscultation data.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

M3DICINE designs and sells AI-enabled wireless electronic stethoscope systems — Stethee Pro for human medicine and Stethee Vet for veterinary use — that pair FDA-cleared hardware with iOS/Android mobile apps and the HIPAA-compliant M3DICINE Central cloud web platform. The AIDA machine learning engine captures heart rate, respiratory rate, and systole/diastole durations in approximately 20 seconds, and the device is restricted to sale to licensed healthcare practitioners per FDA regulations.

Product overview

M3dicine's product portfolio consists of AI-enabled electronic stethoscope hardware devices paired with proprietary mobile applications (iOS and Android) and cloud-based web platforms for data management. The core products are Stethee Pro (human medical) and Stethee Vet (veterinary), which are wireless electronic stethoscopes powered by Machine Learning Algorithms for cardiac and respiratory event detection. Both devices connect via Bluetooth to their respective mobile apps, which provide real-time AI-powered vital sign analysis (heart rate, respiratory rate, systole/diastole durations) in approximately 20 seconds. M3DICINE Central and Stethee Vet Central serve as HIPAA-compliant web portals for healthcare providers to manage patient data, generate reports, and share information across care teams. The AIDA (AI-powered) visualization system across the product line displays cardiac cycles, valve energy levels, and environmental data, with FDA-cleared AI analysis algorithms delivering clinically actionable vital sign data. Note: Stethee Pro and Stethee Vet are currently in development and are not available for sale or commercial distribution.

Differentiator

Problem solved

Functional benefit

Brands

• Stethee Pro: World's first wireless electronic stethoscope with machine learning algorithms for cardiac and respiratory events detection. FDA-cleared Class II medical device for medical diagnostic purposes.
• Stethee Vet
• M3DICINE Central
• AIDA

Products and services

• Stethee Pro World's first wireless electronic stethoscope with FDA-cleared machine learning algorithms for cardiac and respiratory events detection, designed for licensed healthcare practitioners. Captures heart and lung sounds with up to 96X amplification, 5 embedded digital filters, and AI analysis delivering vital sign data (heart rate, respiratory rate, systole/diastole durations) in 20 seconds.
• Stethee Vet World's first AI stethoscope designed for veterinary professionals, featuring custom digital filters that reduce animal fur background noise for clear heart, lung, and body sound capture across species. Includes AIDA intelligence that improves with use, geo-location functionality, and integration with the Stethee Vet Central web dashboard.
• Stethee Pro Mobile App Mobile application for iOS and Android that pairs with the Stethee Pro device via Bluetooth to capture, record, and visualize heart and lung sounds in real-time using FDA-cleared AI algorithms. Detects cardiac and respiratory events in approximately 20 seconds and provides vital sign display, patient file management, and wired or Bluetooth headphone support.
• Stethee Vet App Mobile application for use with the Stethee Vet device, allowing veterinarians and pet owners to record, share, and compare patient cardiac and lung vital signs over time. Includes AIDA intelligence that improves with use and integrates with Stethee Vet Central for data management.
• M3DICINE Central HIPAA-compliant, secure web-based platform that connects with Stethee Pro mobile applications (iOS and Android) to enable healthcare providers to manage patient data, generate and share cardiopulmonary reports, track and monitor baseline vital signs, and securely share data with the wider care team.
• Stethee Vet Central Web-based analytics dashboard for veterinary professionals providing powerful analytics, tracking changes over time, maintaining precise geo-location tagged vital sign data in medical records, and enabling comparison of patient conditions over time for objective follow-up and analysis.

Quantifiable outcome

• Capture of cardiac and respiratory vital signs in just 20 seconds, enabling rapid triage, screening and clinical examination
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core, major and supporting.

• UCSF (University of California, San Francisco)coreStrategic or Co-development PartnerM3DICINE has been working with UCSF and leading academic partners in 11 countries on a global initiative funded by the National Institutes of Health (NIH) to screen for drug-susceptible and drug-resistant tuberculosis. The Stethee Pro 1 device is used as a screening tool and the goal is to develop new AI algorithms for detecting TB. This represents M3DICINE's most significant research partnership, spanning multiple continents.
• MIT (Massachusetts Institute of Technology)coreStrategic or Co-development PartnerProfessor Anthony Sinskey from MIT's Department of Biology, Health Sciences & Technology serves as M3DICINE's Advisory Board Chairman. He is Faculty Director of the MIT Center for Biomedical Innovation (CBI), which draws on expertise from MIT's Schools of Engineering, Science, and Management and the Harvard-MIT Division of Health Sciences and Technology. Professor Sinskey is directly involved in evaluating Stethee's potential across health and wellness industries.
• Prisma HealthcoreStrategic or Co-development PartnerPrisma Health is the largest not-for-profit health organization in South Carolina, serving more than 1.2 million patients annually with 32,000 team members. M3DICINE has established a clinical partnership with Prisma Health for AI algorithm development and clinical validation of the Stethee system in a major US health system setting.
• SRS Life SciencesmajorStrategic or Co-development PartnerSRS Life Sciences and M3DICINE are working together in India towards developing AI-based algorithms for the screening and management of Pneumonia. This partnership represents a regional market development channel for India and a strategic focus on respiratory disease AI development.
• QUT (Queensland University of Technology)supportingTechnology or IntegrationM3DICINE has QUT listed as a Research and Development Partner, indicating collaboration on technology development and research activities.
• UQ (University of Queensland)supportingTechnology or IntegrationM3DICINE has the University of Queensland listed as a Research and Development Partner, indicating collaboration on technology development leveraging UQ's medical and engineering research capabilities.
• Mayo ClinicsupportingStrategic or Co-development PartnerProfessor John Sperling M.D., Co-Vice Chair, Department of Orthopedic Surgery at Mayo Clinic, serves on M3DICINE's Clinical Board. Mayo Clinic is a leading US academic medical center bringing clinical governance and validation expertise to the company's product development.
• Imperial College LondonsupportingStrategic or Co-development PartnerProfessor Ed Nicol, a cardiologist at Imperial College London and Wing Commander Royal Air Force, serves on M3DICINE's Clinical Board. He has published over 100 original papers and is Chair of the NATO Aviation Cardiology Working Group, providing clinical expertise and credibility in cardiology applications.
• Australia Zoo Wildlife HospitalsupportingStrategic or Co-development PartnerRosemary Booth D.V.M., Director of Australia Zoo Wildlife Hospital, serves on M3DICINE's Veterinary Clinical Board. She provides clinical expertise for the Stethee Vet product and has been actively using the device for wildlife health assessments, including commenting publicly on its potential for animal health in rehabilitation and wild settings.
• Texas A&M UniversitysupportingStrategic or Co-development PartnerProfessor Sonya Gordon D.V.M., board-certified cardiologist at Texas A&M University, serves on M3DICINE's Veterinary Clinical Board. She provides specialized veterinary cardiology expertise for the Stethee Vet product development and has endorsed the device publicly.
• National University Hospital SingaporesupportingStrategic or Co-development PartnerDr. Kao Pao-Tang, Consultant Emergency Pediatrician at National University Hospital Singapore, serves on M3DICINE's Clinical Board. He has over 21 years of experience in Children's Emergency Services and is a member of the Pediatric Disaster Field Team and Singapore Armed Forces Tsunami Missions.
• University of SydneysupportingStrategic or Co-development PartnerProfessor Niek Beijernk, Lecturer in Small Animal Medicine at the University of Sydney Veterinary School, serves on M3DICINE's Veterinary Clinical Board. He is a Diplomate of the European College of Veterinary Internal Medicine (Cardiology) and provides specialized veterinary expertise for Stethee Vet product development.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Eko Health: Eko Health is the leading AI-enabled digital stethoscope company (Eko Core, DUO, CORE 500), with FDA-cleared cardiac and pulmonary AI algorithms and major partnerships including 3M Littmann and Mayo Clinic. It is the most direct head-to-head competitor to M3dicine's Stethee Pro, offering the same combination of electronic stethoscope hardware, AI auscultation analysis, and a clinician-facing platform.
• Thinklabs One: Thinklabs One is an electronic/digital stethoscope focused on high-fidelity amplification and digital auscultation, targeting similar clinician use cases (cardiology, telemedicine). It is a smaller direct competitor to Stethee Pro, differentiated more on audio fidelity than on AI analysis.
• StethoMe: StethoMe is a Poland-based AI stethoscope company offering a home-use electronic stethoscope with AI lung-sound analysis, often paired with telehealth platforms for pediatric and respiratory monitoring. It is directly comparable to Stethee Pro in using AI for cardiopulmonary event detection, with a stronger home/telehealth orientation.

Broad incumbents

• 3M Littmann (3M Health Care): 3M Littmann is the dominant incumbent in stethoscopes globally and has its own electronic/digital stethoscope lines (Littmann CORE, in partnership with Eko). It competes with M3dicine across the entire auscultation category and brings massive distribution, brand equity, and clinician relationships that a small entrant like M3dicine must overcome.
• Withings (BPM Core, ScanWatch): Withings produces connected health devices (BPM Core with digital stethoscope/ECG, ScanWatch) targeting consumer and prosumer cardiopulmonary monitoring. It is a broader connected-health incumbent with overlap to M3dicine's vital-signs capture and remote monitoring narrative.
• iRhythm Technologies: iRhythm is a public digital-health company (Zio long-term cardiac monitor) using AI on wearable sensor data for arrhythmia detection. It is comparable to M3dicine as a connected cardiac-AI diagnostic company targeting clinicians, though its modality is continuous ECG patch rather than auscultation.

Emerging players

• HD Medical (Healthy Dynamics): HD Medical develops AI-enabled auscultation and cardiac screening tools (e.g., HD Steth) with a focus on automated murmur and heart-sound detection. It overlaps with M3dicine's AI-driven cardiac auscultation positioning and competes for similar cardiology/primary-care channels.
• AliveCor (KardiaMobile): AliveCor makes FDA-cleared personal ECG devices (KardiaMobile, KardiaMobile 6L) with AI-driven arrhythmia detection and a clinician-facing platform. It overlaps with M3dicine on the cardiac AI and connected-care platform axis, though its core modality is ECG rather than auscultation.
• TytoCare: TytoCare offers a telehealth platform with a handheld device that includes a digital stethoscope, otoscope, and thermometer for remote examinations. It competes with M3dicine in the remote/AI-augmented auscultation and telemedicine segment, especially for primary care and virtual visits.
• Aspen Sound Health (Aarca): Aarca is an emerging AI auscultation platform focused on pediatric and respiratory applications using a digital stethoscope + cloud AI. It is comparable to M3dicine in combining an electronic stethoscope with machine-learning-driven cardiopulmonary analysis for clinical use.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/m3dicinecom
• YouTubeyoutube.com/c/m3dicine
• Facebookfacebook.com/M3DICINE
• LinkedInlinkedin.com/company/m3dicine
• Instagraminstagram.com/m3dicine

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about M3dicine